Title:Anticancer Potential of ACEIs/ARBs Administration in Colorectal
Cancer
Volume: 31
Issue: 30
Author(s): Xin Wang and Haiyun Jing*
Affiliation:
- Department of Cardiology, Zhengzhou Central Hospital, Zhengzhou,
450000, Henan, People's Republic of China
Keywords:
ACE inhibitors, colon cancer, mortality, radiotherapy, ACEIs/ARBs therapy, statistical methods.
Abstract:
Background: Colorectal cancer (CC) is the fourth most common type of cancer
that causes illness and death. Medicines like ACE inhibitors and ARBs, usually used
for heart problems, have shown they might help with the growth and development of
CC.
Introduction: An analysis of ACE inhibitors and colon cancer is conducted in this comprehensive
review. The main goal is to see how ACEIs/ARBs affect the chances of getting
cancer and dying in patients with CC.
Methods: A systematic literature search was conducted to identify relevant studies. Inclusion
criteria encompassed studies that evaluated the use of ACEIs/ARBs in patients
with CC and reported outcomes related to new cancer incidence and mortality. Data
from selected studies were extracted and analyzed using appropriate statistical methods.
Results: The study showed that fewer cancer cases occurred in patients who took
ACEIs/ARBs compared to those who did not (RR 0.962, 95% CI 0.934-0.991, p =
0.010). Furthermore, patients with CC who utilized ACEIs/ARBs exhibited a decreased
mortality rate compared to non-users (HR 0.833, 95% CI 0.640-1.085, p = 0.175).
Conclusion: This review suggests that using ACEIs/ARBs medicine could help people
with CC live longer and lower their chances of dying. These results highlight the potential
benefits of utilizing ACE inhibitors in the management of CC, warranting further investigation
and consideration in clinical practice.
